Alhaddad Ruqaya, Abualsoud Bassam M, Al-Deeb Ibrahim, Nsairat Hamdi
Pharmacological & Diagnostic Research Center, Faculty of Pharmacy, Al-Ahliyya Amman University, Amman, 19328, Jordan.
Department of Clinical Pharmacy, Faculty of Pharmacy, Zarqa University, Zarqa, 13110, Jordan.
Future Sci OA. 2024 Dec 31;10(1):2419806. doi: 10.1080/20565623.2024.2419806. Epub 2024 Nov 14.
ZnO NPs were prepared via green synthesis utilizing . Physical characterization and biological activity were performed against 2D, and 3D spheroids MCF-7 cell lines. The NPs exhibited 188.9, 175.7 and 171.2 nm size with charge of -8.2, -11.7 and -9.7 mV for the 2%, 3% and 4% formulations. XRD confirmed a wurtzite hexagonal phase. FTIR spectra showed Zn-O stretching vibrations. The 2%, 3% and 4% formulations presented IC values of 14.7, 26.2 and 47 μg/ml, respectively, with complete destruction of MCF-7 spheroids. Elevated levels suggested an inflammatory-mediated mechanism of action. 2% -derived ZnO NPs showed antitumor potential against deserving further mechanistic and explorations.
通过绿色合成法制备了氧化锌纳米颗粒(ZnO NPs)。对二维和三维球体MCF - 7细胞系进行了物理表征和生物活性研究。对于2%、3%和4%的配方,纳米颗粒的尺寸分别为188.9、175.7和171.2纳米,电荷分别为 - 8.2、 - 11.7和 - 9.7毫伏。X射线衍射(XRD)证实为纤锌矿六方相。傅里叶变换红外光谱(FTIR)显示了Zn - O伸缩振动。2%、3%和4%的配方的半数抑制浓度(IC)值分别为14.7、26.2和47微克/毫升,MCF - 7球体被完全破坏。水平升高表明存在炎症介导的作用机制。2%的氧化锌纳米颗粒显示出抗肿瘤潜力,值得进一步进行机制和探索研究。
Future Sci OA. 2024-12-31
Pharmaceuticals (Basel). 2023-2-10
BMC Complement Med Ther. 2023-10-3
J Funct Biomater. 2023-1-9
Future Sci OA. 2024-5-23
Nanomedicine (Lond). 2024
Expert Opin Drug Deliv. 2024-3
Expert Opin Drug Deliv. 2024-2
Pathol Res Pract. 2024-2